200 related articles for article (PubMed ID: 25989713)
1. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK.
Valentine WJ; Curtis BH; Pollock RF; Van Brunt K; Paczkowski R; Brändle M; Boye KS; Kendall DM
Diabetes Res Clin Pract; 2015 Jul; 109(1):95-103. PubMed ID: 25989713
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
3. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
[TBL] [Abstract][Full Text] [Related]
4. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
5. Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin: Clinical outcome and cost-effectiveness analyses.
McGlone ER; Carey I; Veličković V; Chana P; Mahawar K; Batterham RL; Hopkins J; Walton P; Kinsman R; Byrne J; Somers S; Kerrigan D; Menon V; Borg C; Ahmed A; Sgromo B; Cheruvu C; Bano G; Leonard C; Thom H; le Roux CW; Reddy M; Welbourn R; Small P; Khan OA
PLoS Med; 2020 Dec; 17(12):e1003228. PubMed ID: 33285553
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial.
Saunders R; Lian J; Karolicki B; Valentine W
J Med Econ; 2014 Dec; 17(12):827-36. PubMed ID: 25168164
[TBL] [Abstract][Full Text] [Related]
7. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
[TBL] [Abstract][Full Text] [Related]
8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
9. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.
Beaudet A; Palmer JL; Timlin L; Wilson B; Bruhn D; Boye KS; Lloyd A
J Med Econ; 2011; 14(3):357-66. PubMed ID: 21563878
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
[TBL] [Abstract][Full Text] [Related]
13. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
Pollock RF; Valentine WJ; Marso SP; Andersen A; Gundgaard J; Hallén N; Tutkunkardas D; Magnuson EA; Buse JB;
Appl Health Econ Health Policy; 2019 Oct; 17(5):615-627. PubMed ID: 31264138
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
Evans M; Chubb B; Malkin SJP; Berry S; Lawson J; Hunt B
Diabetes Obes Metab; 2023 Feb; 25(2):491-500. PubMed ID: 36251282
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
Diabetes Obes Metab; 2019 Apr; 21(4):1010-1017. PubMed ID: 30565386
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
Palmer JL; Goodall G; Nielsen S; Kotchie RW; Valentine WJ; Palmer AJ; Roze S
Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.
Huetson P; Palmer JL; Levorsen A; Fournier M; Germe M; McLeod E
J Med Econ; 2015; 18(8):573-85. PubMed ID: 25853868
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK.
Pollock RF; Muduma G; Valentine WJ
Diabetes Obes Metab; 2013 Feb; 15(2):121-9. PubMed ID: 22882321
[TBL] [Abstract][Full Text] [Related]
20. Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain.
Afonso M; Ryan F; Pitcher A; Lew E
J Med Econ; 2017 Jun; 20(6):633-639. PubMed ID: 28271733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]